biostudies-literatureSchwarz CAustrian Federal Ministry for Digital and Economic AffairsBoehringer IngelheimÖsterreichische Gesellschaft für Gastroenterologie und HepatologieÖsterreichische Nationalstiftung für Forschung, Technologie und EntwicklungChristian Doppler ForschungsgesellschaftClinical Research Groups Program of the Ludwig Boltzmann Gesellschafte70131https://www.ebi.ac.uk/biostudies/studies/S-EPMC12802573biostudies-literatureUnknown14(1)<h4>Background</h4>Complications related to portal hypertension (PH) in patients with alcohol-related liver disease (ALD) can be controlled by transjugular intrahepatic portosystemic shunt (TIPS) placement; however, the impact of ongoing alcohol use (AU) after TIPS remains scarcely investigated.<h4>Methods</h4>ALD patients undergoing TIPS implantation between 2000 and 2022 were included. Laboratory/demographic parameters and clinical events/outcomes were compared per post-TIPS AU status and to a group of n = 55 decompensated ALD patients with ongoing AU who did not receive TIPS.<h4>Results</h4>Overall, 248 TIPS patients (78.2% male; median age: 55.5 years; ascites: 69.8%; median MELD: 12), including 90 (36.3%) with ongoing AU after TIPS were included. AU post-TIPS was independently associaUnited European gastroenterology journalAlcohol Use After TIPS Implantation Significantly Increases the Risk of ACLF and Liver-Related Death.PMC12802573LBG_KFG_22_32Mullner-Bucsics TSchwarz CKappel JTrauner MAbid RMandorfer MSimbrunner BKramer GJachs MDominik NReider LKornfehl AReiberger TSchwarz MHartl LHofer BSfalseAlcohol Use After TIPS Implantation Significantly Increases the Risk of ACLF and Liver-Related Death.<h4>Background</h4>Complications related to portal hypertension (PH) in patients with alcohol-related liver disease (ALD) can be controlled by transjugular intrahepatic portosystemic shunt (TIPS) placement; however, the impact of ongoing alcohol use (AU) after TIPS remains scarcely investigated.<h4>Methods</h4>ALD patients undergoing TIPS implantation between 2000 and 2022 were included. Laboratory/demographic parameters and clinical events/outcomes were compared per post-TIPS AU status and to a group of n = 55 decompensated ALD patients with ongoing AU who did not receive TIPS.<h4>Results</h4>Overall, 248 TIPS patients (78.2% male; median age: 55.5 years; ascites: 69.8%; median MELD: 12), including 90 (36.3%) with ongoing AU after TIPS were included. AU post-TIPS was independently associa2026-01-01T00:00:00Z2026 Feb2026-06-06T14:53:23.035Z2026-06-01T03:07:25.08ZS-EPMC128025734128840210.1002/ueg2.70131